Silo Pharma, Inc. (SILO)
Every figure below is the company's own, as filed. Nothing is estimated and
nothing is smoothed — a period the filing does not support is left blank rather than
drawn.
Quarters are the company's own, counted from its financial
year ending 12-31.
Amounts in USD.
Every figure as a table ›
Revenue Quarterly
0
25K
50K
75K
Q1 '21: 47.4K
Q2 '21: 68.1K
Q1 '22: 18K
Q2 '22: 18K
Q3 '22: 18K
Q4 '22: 18K
Q1 '23: 18K
Q2 '23: 18K
Q3 '23: 18K
Q4 '23: 18K
Q1 '24: 18K
Q2 '24: 18K
Q3 '24: 18K
Q4 '24: 18K
Q1 '25: 18K
Q2 '25: 18K
Q3 '25: 18K
Q4 '25: 18K
Q1 '26: 18K
Q2 '26: 0
Q2 '21
Q3 '22
Q2 '23
Q1 '24
Q4 '24
Q3 '25
Q2 '26
Gross Profit Quarterly
-6K
0
6K
12K
18K
Q3 '21: 16.6K
Q4 '21: 16.6K
Q1 '22: 16.6K
Q2 '22: 16.6K
Q3 '22: 16.6K
Q4 '22: 16.6K
Q1 '23: 16.6K
Q2 '23: 16.6K
Q3 '23: 16.6K
Q4 '23: 16.6K
Q1 '24: 16.6K
Q2 '24: 16.6K
Q3 '24: 16.6K
Q4 '24: 16.6K
Q1 '25: 16.6K
Q2 '25: 16.6K
Q3 '25: -2.7K
Q4 '25: -2.7K
Q1 '26: -2.7K
Q2 '26: 0
Q4 '21
Q3 '22
Q2 '23
Q1 '24
Q4 '24
Q3 '25
Q2 '26
Operating Income Quarterly
-2.1M
-1.4M
-700K
0
700K
1.4M
2.1M
Q3 '21: -463.9K
Q4 '21: -942.4K
Q1 '22: -527.3K
Q2 '22: -494.3K
Q3 '22: -949.2K
Q4 '22: -1.7M
Q1 '23: -803.5K
Q2 '23: -1.1M
Q3 '23: -773.4K
Q4 '23: -1.2M
Q1 '24: -879.5K
Q2 '24: -1M
Q3 '24: -1M
Q4 '24: -1.8M
Q1 '25: -1.1M
Q2 '25: -1.2M
Q3 '25: -1.2M
Q4 '25: -786.5K
Q1 '26: -1.6M
Q2 '26: -928.9K
Q4 '21
Q3 '22
Q2 '23
Q1 '24
Q4 '24
Q3 '25
Q2 '26
Net Income Quarterly
-2.5M
0
2.5M
5M
7.5M
Q3 '21: 6.4M
Q4 '21: -1.1M
Q1 '22: -604.1K
Q2 '22: -658.4K
Q3 '22: -983.2K
Q4 '22: -1.7M
Q1 '23: -906.4K
Q2 '23: -1M
Q3 '23: -660.2K
Q4 '23: -1.1M
Q1 '24: -801.7K
Q2 '24: -931.8K
Q3 '24: -928.8K
Q4 '24: -1.7M
Q1 '25: -1M
Q2 '25: -1.2M
Q3 '25: -1.1M
Q4 '25: -881.5K
Q1 '26: -1.6M
Q2 '26: -832.8K
Q4 '21
Q3 '22
Q2 '23
Q1 '24
Q4 '24
Q3 '25
Q2 '26
Cost of Revenue Quarterly
0
8K
16K
24K
Q3 '21: 1.5K
Q4 '21: 1.5K
Q1 '22: 1.5K
Q2 '22: 1.5K
Q3 '22: 1.5K
Q4 '22: 1.5K
Q1 '23: 1.5K
Q2 '23: 1.5K
Q3 '23: 1.5K
Q4 '23: 1.5K
Q1 '24: 1.5K
Q2 '24: 1.5K
Q3 '24: 1.5K
Q4 '24: 1.5K
Q1 '25: 1.5K
Q2 '25: 1.5K
Q3 '25: 20.7K
Q4 '25: 20.7K
Q1 '26: 20.7K
Q2 '26: 0
Q4 '21
Q3 '22
Q2 '23
Q1 '24
Q4 '24
Q3 '25
Q2 '26
Operating Cash Flow Quarterly
-1.8M
-1.2M
-600K
0
600K
1.2M
1.8M
Q3 '21: -663.1K
Q4 '21: -773.9K
Q1 '22: -789.2K
Q2 '22: -400.1K
Q3 '22: -1.4M
Q4 '22: -886K
Q1 '23: -692.7K
Q2 '23: -550K
Q3 '23: -1.1M
Q4 '23: -910K
Q1 '24: -838.2K
Q2 '24: -731.8K
Q3 '24: -1.3M
Q4 '24: -917.4K
Q1 '25: -1.6M
Q2 '25: -1.3M
Q3 '25: -955.5K
Q4 '25: -780.3K
Q1 '26: -822.6K
Q2 '26: -781.9K
Q4 '21
Q3 '22
Q2 '23
Q1 '24
Q4 '24
Q3 '25
Q2 '26
Shares Outstanding Quarterly
0
35M
70M
105M
Q2 '19: 23.4M
Q3 '19: 23.5M
Q3 '20: 84.4M
Q1 '21: 85.1M
Q2 '21: 96.9M
Q3 '21: 2M
Q1 '22: 2M
Q2 '22: 2M
Q3 '22: 2M
Q1 '23: 3.2M
Q2 '23: 3.2M
Q3 '23: 3.1M
Q1 '24: 2.9M
Q2 '24: 3.1M
Q3 '24: 4.3M
Q1 '25: 4.5M
Q2 '25: 418.6K
Q3 '25: 9.3M
Q1 '26: 13.7M
Q2 '26: 1.1M
Q3 '19
Q2 '21
Q2 '22
Q2 '23
Q2 '24
Q2 '25
Q2 '26
Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.
EPS TTM
-4.50
-3.00
-1.50
0.00
1.50
3.00
4.50
Q4 '19: -0.04
Q1 '20: -0.04
Q2 '20: -0.07
Q3 '20: -0.07
Q4 '20: -0.07
Q1 '21: -0.06
Q2 '21: -0.02
Q3 '21: 3.15
Q4 '21: 0.04
Q1 '22: 0.04
Q2 '22: 0.04
Q3 '22: -3.61
Q4 '23: -1.20
Q1 '24: -1.19
Q2 '24: -1.18
Q3 '24: -1.19
Q4 '24: -1.22
Q1 '25: -1.17
Q2 '25: -3.74
Q3 '25: -3.64
Q1 '20
Q4 '20
Q3 '21
Q2 '22
Q1 '24
Q4 '24
Q3 '25
The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.
Not drawn for SILO:
Free Cash Flow . Nothing in this filer's XBRL supports
it for the periods asked for. That is a gap in
the filing, not a zero, and drawing a flat line would be an invention.